Has Inflammation a Significant Implication in Lung Cancer Evolution?

European Lung Cancer Working Party400 enrolled

Overview

Systemic inflammation is a potential prognostic factor in cancer. Inflammation scores as the Glasgow score have been tested in cancer and specifically in lung cancer patients. The aim of the study is to look at the prognostic and predictive value of inflammation during cancer evolution, on the risk of complications leading to ICU admission and the risk of death.

Patients with newly diagnosed lung cancer will be eligible. All patients will have a blood sampling allowing testing inflammation and cytokine analyses at diagnosis, during work-up and in case of complication.

Study Type

OBSERVATIONAL

Enrollment

400

Conditions

Lung Neoplasms

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Lung neoplasms irrespective of stage, histology Exclusion Criteria: * Previously treated lung neoplasms * A history of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or cured malignant tumour (more than 5 year disease-free interval)

Locations (1)

Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet

Brussels, Belgium

Outcomes

Primary Outcomes

Survival

Time frame: Measured from diagnosis until death or last date known to be alive, or at least 48 months

Secondary Outcomes

Complications leading to emergency/ICU

Recording any complication leading to consultation at the emergency department or admission into the intensive care unit

Time frame: From inclusion until death, or a least 48 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.